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Research in context 
Evidence before this study 
The importance of host immunity in the pathogenesis and outcome of diffuse large B 
cell lymphoma (DLBCL) is established. However the impact of the relative composition 
of immune effectors and checkpoints within the tumour microenvironment on 
prognosis is unknown. New digital hybridization technologies permit rapid 
quantification of gene expression on paraffin embedded biopsies, and can be applied 
to the evaluation of intratumoural immunity. 
 
Added value of this study 
Using a discovery / validation biomarker approach, we developed and tested a novel 
immune score that quantifies the ratio of immune effectors and checkpoints. The score 
generated widely disparate progression free and overall survival curves that were 
independent of and additive to conventional clinical and biological prognosticators. 
 
Implications of all the available evidence 
New targeted, biologic and immunotherapeutic agents show activity in DLBCL, and in 
time, may have a role in first-line treatment for some patients. Therefore, identification 
of prognostic biomarkers that distinguish patients with low likelihood of cure to 
conventional first-line therapies such as R-CHOP is a priority. The present study 
illustrates the importance of incorporating assessment of the tumour 
microenvironment with conventional clinical and biologic approaches to improve 
prognostication. Furthermore, based on the evidence in studies of checkpoint-
blockade, an immune score may also have potential implications for selection of 
patients for checkpoint-blockade within clinical trials. 
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Abstract   
Background: Risk-stratification of diffuse large B-cell lymphoma (DLBCL) requires 
identification of patients with disease that is not cured despite initial R-CHOP. Although 
the prognostic importance of the tumour microenvironment (TME) is established, the 
optimal strategy to quantify it is unknown.  
Methods: The relationship between immune-effector and inhibitory (checkpoint) genes 
was assessed by NanoString™ in 252 paraffin-embedded DLBCL tissues. A model to 
quantify net anti-tumoural immunity as an outcome predictor was tested in 158 R-
CHOP treated patients, and validated in tissue/blood from two independent R-CHOP 
treated cohorts of 233 and 140 patients respectively. 
Findings: T and NK-cell immune-effector molecule expression correlated with tumour 
associated macrophage and PD-1/PD-L1 axis markers consistent with malignant B-
cells triggering a dynamic checkpoint response to adapt to and evade immune-
surveillance. A tree-based survival model was performed to test if immune-effector to 
checkpoint ratios were prognostic. The CD4*CD8:(CD163/CD68)*PD-L1 ratio was 
better able to stratify overall survival than any single or combination of immune 
markers, distinguishing groups with disparate 4-year survivals (92% versus 47%). The 
immune ratio was independent of and added to the revised international prognostic 
index (R-IPI) and cell-of-origin (COO). Tissue findings were validated in 233 DLBCL 
R-CHOP treated patients. Furthermore, within the blood of 140 R-CHOP treated 
patients immune-effector:checkpoint ratios were associated with differential interim-
PET/CT+ve/-ve expression.  
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Interpretation: Ratios of immune-effectors to checkpoints augment COO and R-IPI in 
DLBCL, are applicable to paraffin-embedded biopsies, and have potential implications 
for selection of patients for checkpoint-blockade within clinical trials. 
Funding: Leukaemia Foundation of Queensland, Kasey-Anne Oklobdzijato Memorial 
fund, the Australasian Leukaemia and Lymphoma Group (Malcolm Broomhead 
Bequest), the Australian Cancer Research Foundation and the Cancer Council of 
Queensland. Roche provided funds towards the clinical running of the ALLGNHL21 
Clinical Trial.  
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Introduction 
Diffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell lymphoma. 
Approximately ~30% of patients remain refractory or relapse following initial therapy 
with regimens such as R-CHOP.1  New therapeutic strategies are in development, but 
their application requires accurate identification of patients likely to fail induction. 
However, despite the use of established pre-treatment prognosticators such as the 
cell-of-origin (COO) and international prognostic index (IPI) and/or revised-
international prognostic index (R-IPI),2,3 considerable heterogeneity of outcome 
persists.1 There is a pressing need to develop tools that add to the predictive power 
of conventional prognosticators to more accurately predict response to initial therapy. 
Lymphomatous B-cells develop within a complex tumour microenvironment 
(TME) that influences their growth and spread. Data strongly implicates immune 
deficiencies in lymphoma pathogenesis and outcome.4 For example recent data in 
murine models shows the importance of CD8+ T-cells in the prevention of of 
lymphoma,5 and adoptive T-cell therapy has shown clinical benefit for the treatment of 
immunosuppression related lymphomas.6 Furthermore, circulating monocytes have 
active roles in DLBCL control.7,8 It has recently been established that patients with low 
peripheral blood absolute lymphocyte:monocyte ratios (LMR) have inferior 
outcomes.9-11 Within peripheral blood monocytes, the CD14+HLA-DRlo ‘monocytoid-
myeloid-derived-suppressor cells’ (moMDSC) subset is associated with higher rates 
of disease progression in patients with B-cell lymphoma.12-14 DLBCL biopsies are 
enriched in TAMs.2,15,16 TAMs are thought to be immunosuppressive ‘M2’ 
macrophages. TAMs derived from primary tumours are believed to facilitate circulating 
tumour cell seeding of distant metastases in solid-organ cancers.17 Although it is 
known that monocytes can migrate to lymph nodes and differentiate into 
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macrophages, the relationship between moMDSC and TAMs is incompletely 
understood.5,9 DLBCL biopsies also display other features of an inhibitory host-
checkpoint response, which is exploited by malignant B-cells to dampen anti-tumour 
immune-effectors to foster lymphoma cell survival.2,16,18 These include enrichment in 
PD-1/PD-L1-axis molecules.19 PD-L1 expression on antigen-presenting cells 
promotes regulatory T-cells, whereas sustained expression of PD-1 inhibits NK-cells. 
Both result in impaired anti-tumour immunity.20 The impact of the PD-1/PD-L1 axis on 
the survival of patients with DLBCL after front-line therapy is still to be established. 
In solid-organ cancers, tumour biopsies display ‘adaptive resistance’ in which 
checkpoints are triggered in response to immune-effectors.21 Whether a similar 
relationship between immune-effectors and checkpoints is present in DLBCL remains 
to be determined. The interplay between immune-effectors and checkpoints within the 
TME may have prognostic importance. Furthermore modulation of immune-
checkpoints has anti-lymphoma activity.22 However the optimal strategy to quantify net 
anti-tumoural immunity is unknown. We considered that a composite measure, 
incorporating the antagonistic forces of immune-effectors and checkpoints, might add 
to the prognostic ability of R-IPI and malignant B-cell biology. The measure must be 
applicable to formalin-fixed, paraffin-embedded (FFPE) tissues to translate to the 
diagnostic laboratory. We utilized digitalized hybridization (NanoString™) to quantify 
candidate immune-effector and checkpoint molecules in DLBCL FFPE tissues in an 
R-CHOP-treated cohort.23-25 Ratios of immune-effectors:checkpoints identified patient 
groups with disparate survival, independent of R-IPI and COO. Using supportive 
approaches, findings were validated in fresh-frozen tissues and pre-therapy blood in 
373 patients from two independent cohorts. The data has potential implications for 
selection of patients for checkpoint-blockade within clinical trials. 
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Methods 
Patients 
The study was approved by Ethics Committees at participating sites. The initial 
tissue cohort comprised 252 patients with histologically confirmed DLBCL. All patients 
received R-CHOP, and were otherwise selected solely on the basis of FFPE tissue 
availability. Only de-novo cases of DLBCL were included. Grade IIIB or transformed 
follicular lymphoma, HIV-positive and post-transplant patients were excluded. This 
cohort was tested for correlation of immune-effectors with checkpoints. Tissue from 
63 patients was obtained from the Australasian Leukaemia and Lymphoma Group 
(ALLG) Discovery Centre (DC). In these patients no follow-up data was available. The 
remaining 189 patient samples were obtained from two tertiary referral centres 
(Princess Alexandra Hospital, Brisbane, and Canberra Hospital). All 189 patients 
received R-CHOP immunochemotherapy. Patients were selected solely on the basis 
of FFPE tissue availability. Survival data was available in all but 31 patients. The 
remaining 158 cases were tested for the impact of immune-effector:checkpoint ratios 
on prognosis. For validation of the generated model’s findings we utilized a publicly 
available data-set in which gene expression was quantified on fresh-frozen samples 
using an Affymetix platform.16 
Blood assays were planned prospectively within the ALLGNHL21 DLBCL trial 
(Clinical Trials Identifier: ACTRN12609001077257 and Appendix Page 1). Peripheral 
blood mononuclear cells (in dimethyl sulfoxide) and plasma were cryopreserved, 
thawed, and tested in batches as previously outlined.26 Following a centrally-reviewed 
interim-PET/CT scan on days 17-20 of cycle 4, patients received risk-stratified therapy. 
Blood samples were collected ‘pre-therapy’ and day 21 of the fourth cycle of R-CHOP 
‘post-cycle 4’. The principle endpoints of the ALLGNHL21 clinical trial (OS and event-
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free survival) in patients undergoing risk-stratified therapy remain to be reached. For 
comparison, blood was also taken from 22 healthy participants (median age 57 years, 
range: 37-68; females 7 of 22 i.e. 32%) without malignancy or autoimmunity. There 
were no significant differences between the age (P=0.8) and the gender (P=0.9) of 
healthy participants and the ALLGNHL21 cohort. All participants gave written informed 
consent. The study is reported according to the STROBE statement http://www.strobe-
statement.org/.  
 
RNA quantification 
RNA was extracted from FFPE tumour-biopsies using RecoverAll (Ambion, 
Carlsbad, CA, USA) and stored at -80oC. Genes were quantified (Appendix Page 1) 
using the NanoString™ platform (Seattle, WA, USA).  
 
Protein Quantification 
Enzyme linked immuno-absorbent assays (ELISA) for plasma levels of CD163 
(R & D Systems, Minneapolis, USA, at a 1:20 dilution) and PD-L1 (PDCD1LG1 ELISA 
kit, USCN Life Science, Wuhan, China, performed neat) were tested in duplicates 
(CD163) and triplicates (PD-L1) and quantified as previously outlined.27,28 Flow 
cytometry data was acquired using a BD LSRII flow cytometer (BD, Australia). Isolated 
monocytes were tested for arginase activity using the Urea assay kit (Abnova Urea 
Assay, Taiwan). This assay measures the metabolite urea, a by-product of arginine 
degradation. 
 
Statistical analysis  
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 Values between groups of data were tested for statistical significance using the 
2-tailed paired (e.g. between time-points) or, where appropriate unpaired t-tests. 
Categorical data were compared using Fisher’s exact test or Chi-squared test as 
appropriate. R-IPI was categorized as ‘very good/good’ (VG/G) equivalent to IPI 0-2, 
and ‘Poor’ equivalent to IPI:3-5. Progression free survival (PFS) was measured from 
diagnosis to date of last follow-up or disease progression, death, or discontinuation of 
treatment for any reason. Overall survival (OS) was measured from diagnosis to date 
of last follow-up or death. COO was initially classified as germinal centre B-cell (GCB), 
activated B-cell (ABC) and unclassified (UC). The OS for GCB was superior to ABC 
(P=0.0027). Consistent with this we also observed superior survival for GCB against 
ABC and UC combined (‘non-GCB’ P=0.018). Similarly across all three groupings 
(GCB, ABC and UC) superior survival for GCB was seen (P=0.01). In line with 
proportions observed by researchers at the National Institutes of Health,29 the UC 
cohort made up a minority subset of 13% (20/158). Given that OS for the UC cohort 
was not different from that of ABC (P=0.28), these were combined to permit 
dichotomization into two cohorts (GCB and non-GCB).  
 To assess the prognostic value of each single marker and each ratio, survival 
analysis was performed using tree-structured statistical models. This was followed by 
a two-sample test to test the difference between survival curves. P values in the tree-
structured model were adjusted using the Bonferroni multiple correction procedure 
(Appendix Page 2). The model determines an optimal cut-off for each ratio (or single 
marker) to stratify patients into two survival subgroups. Survival analysis was 
performed using Kaplan–Meier method and compared using the log-rank test. 
Multivariable analysis was performed using Cox Regression and proportional hazards 
were verified using a log minus log plot (see Appendix Page 7). All P-values are two-
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sided, except those in the validation groups which are one-sided in the direction of the 
observed training group effect, as per Lenz et al.16  
 
Role of the funding source 
The funders of the study had no role in study design, data collection, data analysis, 
data interpretation, or writing of the report. The corresponding author had full access 
to all the data and had final responsibility for the decision to submit for publication. 
Those with access to raw data were CK, FV, MH, KLC, MRG, EH, PC, KJ, MKG. 
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Results 
Correlation of immune-effectors with checkpoints 
In keeping with previous reports using NanoString™,24,25 we observed strong 
Spearman correlation between gene expression in three paired frozen/FFPE samples 
across a range of genes (Appendix Page 8), indicating the validity of this approach for 
RNA quantification on FFPE biopsies. We then tested correlations between immune-
effector and checkpoints quantified by NanoString™ in 252 FFPE tissues. Immune-
effectors were CD137 (for T and NK-cell activation),30 CD4, CD8 and CD56. TAM and 
PD-1/PD-L1-axis checkpoints were PD-1, PD-L1, CD163 and CD68. Correction for 
multiple testing was applied.31 Consistent with a dynamic interplay between the 
inhibitory checkpoint response (initiated by the host to evade destruction) and 
immune-effector activation, highly significant correlations of all immune-effectors was 
observed for virtually all checkpoints ranging from up to 10-31 (CD4), 10-15 (CD8), 10-5 
(CD56), and 10-12 (CD137). The strength of correlations were modest and variable, 
reflecting the variation between patients in mounting an effective anti-lymphoma 
immune response (Appendix Page 4). 
 
Immune-effector:checkpoint ratios as a measure of net anti-tumoural immunity 
within the TME. 
The cohort of 158 patients with outcome data were utilized (Table 1). From the 
initial tissue cohort of 252 patients, we excluded 63 from the ALLGDC and the 31 from 
the two tertiary referral centres as no outcome data was available. Median age of the 
158 patients was 62 years, range 27-86. Median follow-up was 3.9 years (inter-quartile 
range 2.55-5.88 years).  
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The correlations of immune-effector and checkpoint suggest that identification 
of elevated immune-effector molecules per se, might not be associated with improved 
outcome if accompanied by a checkpoint response of sufficient magnitude to counter 
anti-lymphoma immunity. We hypothesized that the ratios of TME immune-effectors 
to checkpoints would better predict outcome than quantification of any single immune 
marker in isolation. A survival analysis (using OS as the read-out) was run using a 
tree-structured survival model testing all 65 combinations of single markers and ratios. 
Correction for multiple testing using the Bonferroni procedure was applied. Immune-
effectors were numerators of the ratios. The denominators were the checkpoints PD-
1, PD-L1, CD163, CD68 and ‘M2’ (defined as the ratio of CD163:CD68 checkpoint 
molecules). The rationale for including M2 was that the combination of CD68 and 
CD163 was likely to be more informative than either checkpoint alone.32 M2 was 
prognostic (P-value adjusted for multiple testing P=0.0056) whereas CD163 and CD68 
alone were not.  
The tree-structured model identified a number of prognostic immune molecule 
combinations. Optimal cut-off values were determined so as to best segregate survival 
times. They were computed on the whole cohort and scaled (to enable a digital versus 
linear comparison). The advantage of this approach is that this same cut-off value can 
be applied to any other patient cohort, provided that the same platform is used to 
measure their expression levels. Since each ratio was scaled, negative cut-offs reflect 
combinations in which the expression ratio is less than the average expression value 
of that combination across the whole cohort. Within the top ten combinations (based 
on the tree-based survival curve tests), CD4, CD8, CD137, CD56 as numerators, and 
M2, PD-1 and PD-L1 as denominators were all present, with all except CD56 occurring 
frequently (≥ seven times). The most efficient and highest ranked combination (with a 
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cut-off -0.278958829 to enable the score to be dichotomized into a categorical variable 
into low and high-ratio groupings) was the products of the immune-effectors CD4 and 
CD8, in a ratio with the products of M2 and PD-L1 (the CD4*CD8:M2*PD-L1 immune 
ratio). This required only five genes to give a widely disparate 4-year OS, and was 
selected for further testing. Using Kaplan–Meier and the log-rank test, the 
CD4*CD8:M2*PD-L1 ratio separated patients into disparate high and low-ratio 4 year 
survivals that differed by 45% (Figure 1A, P<0.0001). The proportion of patients in 
high and low-ratio groups were 59% (93/158) and 41% (65/158). Immune score was 
also highly discriminatory for PFS (Appendix Page 8, P<0.0001). 
 
Immune-effector:checkpoint ratios adds to conventional prognosticators. 
Both R-IPI and COO separated patients into prognostic groupings: P=0.002 
and P=0.018 and 4-year survivals of VG/G 83% (CI 90.1-71.8%) versus Poor 61% (CI 
72.5-46.3%), and GCB 82% (CI 90.5-74%) versus non-GCB 60% (71.8-43%) 
respectively. There were 152 of 158 patients with R-IPI data. The number of patients 
grouped as VG/G were n=88 and Poor n=64. For COO, there were n=104 for GCB 
and n=54 for non-GCB. 
Application of the immune ratio CD4*CD8:M2*PD-L1 into low and high-ratio 
groupings, sub-stratified R-IPI and COO (Table 2 and Figure 1B-E). For R-IPI, 37% of 
patients (56/152) were in the best survival groupings (VG/G R-IPI and high-ratio 
immune score), with ~20% (32/152 VG/G low immune; 33/152 Poor high immune; 
31/152 Poor low immune) in each of the other categories (Table 2). Similarly for COO, 
for GCB and high immune score there were 43% of patients (68/158) and ~20% in 
each of the other categories (36/158 GCB low immune; 25/158 non-GCB high 
immune; 29/158 non-GCB low immune). Combining the immune ratio with R-IPI and 
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COO created two clearly separate groupings (Figure 1F): Poor R-IPI-low-ratio and/or 
non-GCB-low-ratio (4-year OS=40% (CI 55.1-24.3%), termed poor-risk), versus all 
other groupings (4-year OS=89% (CI 94.3-79.3%, good-risk). Thirty percent of patients 
had a poor-risk combined R-IPI-COO-immune score. A higher proportion of high-ratio 
immune score patients were in GCB than non-GCB (68/104 i.e. 65% versus 25/54 i.e. 
46% P=0.026). However a similar proportion of high immune score patients were in 
VG/G R-IPI to poor R-IPI (33/64 i.e. 51% versus 54/88 i.e. 62% P=0.18). Importantly, 
in Cox Regression multivariable analysis the significance remained, with the immune 
ratio independent of COO and R-IPI (P<0.0001, with COO P=0.048 and R-IPI P=0.01, 
Appendix Page 4). 
 
External validation of immune ratios using the Affymetrix platform on frozen 
tissue. 
The commonly accepted way to validate the results would be to seek an 
external cohort with a sample size calculated from the results obtained in the discovery 
NanoString cohort. However, no publically available NanoString cohort with these 
genes is available. Therefore, we applied the immune ratio to an independent cohort 
of 233 R-CHOP-like treated patients in which gene expression was quantified on fresh-
frozen samples using an Affymetrix platform (Table 1).16 An identical cut-off was used, 
scaled to be applicable to Affymetrix. The immune ratio segregated patients into 
groupings with significantly different survivals (Appendix Page 9). 60% (139/233) of 
patients had a high-ratio, almost identical to that seen for the Australian-tissue cohort. 
As with the discovery cohort, a higher proportion of high-ratio immune score patients 
were in GCB than non-GCB (73/107 i.e. 68% versus 66/126 i.e. 52% P=0.016), and a 
similar proportion of high immune score patients were in VG/G R-IPI to poor R-IPI 
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(36/66 i.e. 55% versus 81/133 i.e. 61% P=0.44). By multivariable analysis the ratio 
was independent of COO and R-IPI (immune ratio P=0.017, COO P=0.011 and R-IPI 
P<0.0001 respectively, Appendix Page 4). 
 
Circulating immune-effector:checkpoint ratios are associated with differential 
interim-PET/CT status. 
Circulating immune-subsets are established as surrogate markers of 
intratumoural immunity.7-11,33 Detailed assessment of circulating immune-effector and 
checkpoints from the prospective ‘ALLGNHL21’ poor-risk DLBCL trial (Table 1) was 
used as a confirmatory strategy to validate the tissue findings. The overall rate of 
interim-PET/CT-positivity was 40/140 patients i.e. 29%. Patients with interim-
PET/CT+ve had elevated PD-1 expression on CD4, CD8 and NK-cells compared with 
interim-PET/CT-ve patients (Figure 2A-C). Similarly, CD163+moMDSC were higher in 
those remaining PET/CT+ve (Figure 2D).  
To test if blood was consistent with tissue findings, correlations of immune-
effectors were performed. CD8+ T-cells and CD163+moMDSC were again modestly 
but significantly correlated (r=0.42, P=0.0016), again in keeping with an inter-
connected effector-checkpoint response. Accordingly ratios of CD8, CD4 and NK-cells 
divided by CD163+moMDSC markedly enhanced the distinct between interim-
PET/CT+ve/-ve patients (Figure 2E-G). Neither individual R-IPI parameters nor the R-IPI 
were associated with interim-PET/CT treatment response (data not shown).  
 
Circulating immune-effectors and checkpoints in DLBCL 
Circulating immune-effectors and checkpoints were further characterized in 
patients with available samples and compared to healthy participants. Pre-therapy, the 
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mean fluorescent intensity (MFI) of the checkpoint PD1 on CD4+ and CD8+ T-cells and 
NK-cells was strikingly diminished (Figure 2A-C), as was NK-cell activation (measured 
by expression of CD137 during Rituximab-Antibody Dependent Cellular Cytotoxicity, 
Appendix Page 10).  
The immunosuppressive monocytoid-myeloid derived suppressor 
cell ‘moMDSC’ monocyte-subset (defined as CD14+HLA-DRlo)21 were ~2-fold elevated 
(P<0.0001). Interestingly moMDSC and CD163+monocytes values correlated (r=0.41, 
P<0.0001), and pre-therapy CD163+moMDSC were ~4-fold raised (P=0.001). CD163 
MFI correlated with arginase activity and PD-L1 was higher in CD163himoMDSC 
relative to CD163lomoMDSC (Appendix Page 10), consistent with CD163 as a marker 
of immunosuppressive function. A higher proportion of CD163himoMDSC expressed 
lymphoid migratory markers CD62L and CSF-1R implicating transit to nodal tissues. 
CD68 was enriched in moMDSC but equivalent in CD163himoMDSC versus 
CD163lomoMDSC. 
  
Soluble CD163 is associated with adverse clinical features. 
To further explore the importance of CD163 and PD-L1, the plasma soluble 
proteins (sCD163 and sPD-L1) were quantified in healthy participants and the paired 
pre-therapy and post-cycle 4 plasma of patients with DLBCL. Pre-therapy sCD163 
levels were higher and receiver operator curve (ROC) analysis was highly 
discriminatory versus healthy participants (Figure 3A-B). Similarly, sPD-L1 pre-
therapy was higher and highly discriminatory (Appendix Page 11), however, sCD163 
and sPD-L1 were not correlated.  
Pre-therapy sCD163 levels were associated with lymphopenia, advanced 
stage, age and IPI (Figure 3C-F), but sPD-L1 was not associated with these clinical 
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parameters. Neither pre-therapy sCD163 nor sPD-L1 were differentially expressed in 
interim-PET/CT+ve/-ve patients (P=0.72 and P=0.53 respectively). Also post-cycle 4 
sCD163 and sPD-L1 were not associated with interim-PET/CT status (P=0.73 and 
P=0.2 respectively). Levels of sCD163 declined by post-cycle 4, but were still elevated 
relative to healthy participants (P<0.0001). Conversely post-cycle 4 sPD-L1 remained 
at similar levels to pre-therapy and was elevated relative to controls (P=0.0003). 
Results of correlation tests between circulating sCD163 and sPD-L1 and circulating 
immune-effectors and checkpoints cell subsets in blood taken pre-therapy, are shown 
in the Appendix Page 3. 
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Discussion 
In solid-organ cancers the more intense the immune-effector response, the 
more robustly the tumour triggers an inhibitory checkpoint response to adapt to and 
evade immune-surveillance.21 However in DLBCL, the relationship between immune-
effectors and checkpoints is not well-described. We demonstrate in both tissue and 
the blood that immune-effectors correlate with checkpoints, in keeping with a dynamic 
(not constitutive) immune response in which checkpoints are activated in response to 
host anti-lymphoma immunity. This implies that the products of immune-effector 
molecules in a ratio with the products of immune-checkpoints will reflect the balance 
of net anti-tumoural immunity and might have prognostic value.  
The immune ratio (CD4*CD8:[CD163:CD68]*PD-L1) was identified for further 
evaluation. Notably, the denominator itself also included a ratio (CD163:CD68). TAMs 
are classified as either ‘M1’ (CD163loCD68hi) which are anti-tumoural, or ‘M2’ 
(CD163hiCD68hi) that are tumour promoting. However, the M1 and M2 phenotypes 
represent a wide spectrum, which a single marker alone (e.g. CD163) is unable to 
reflect. Thus in patients with DLBCL, the combination of CD163 with CD68 is more 
prognostic than either marker alone.32 In keeping with this, we found the CD163:CD68 
ratio (as a measure of M2-TAMs) was more informative than either marker alone. The 
CD4*CD8:M2*PD-L1 immune ratio high and low survival curves were distinct, and the 
ratio was independent of COO and R-IPI. It should be emphasized that potential bias 
in the results of this population based cohort cannot be excluded, because survival 
data was unavailable in 31 of 189 patients, i.e. these 31 patients may potentially be 
enriched with those that display survival and gene expression characteristics distinct 
from the remaining 158 patients. However, findings were validated in the ‘Lenz’ R-
CHOP-like cohort using an alternative platform on frozen tissues.16 Here the 
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separation between high and low survival curves remained distinct but was less 
pronounced, perhaps reflecting the heterogeneity of the ‘R-CHOP-like’ treatment 
regimens, compared to uniform treatment with R-CHOP in the Australian-tissue 
cohort. 
For practical application, a new prognosticator must segregate patients into 
distinct categories containing a high proportion of patients. It must also be independent 
of (by multivariable analysis) and yet enhance the discriminatory ability of R-IPI and 
COO. R-IPI is influenced by patient fitness, age and tumour burden, whereas COO 
reflects B-cell differentiation. Interestingly for COO (but not R-IPI) there was a modest 
enrichment of the high immune score category within GCB in both the discovery and 
validation cohorts. This result is consistent with an interplay between the malignant B-
cell and the TME. The combination of net anti-tumoural immunity using the immune 
ratio with either COO or R-IPI better distinguished patients than R-IPI or COO alone. 
For example the application of immune ratio to R-IPI segregated patients into 
groupings with four distinct, well-spaced 4-year survival outcomes of 98% (CI 99.7-
87.0%), 80% (CI 91.5-61%), 52% (CI 70.6-29.1%) and 44% (CI 61.4-25%). Strikingly, 
37% (56/152) of patients were in the 98% survival grouping, with ~20% (31-33/152) in 
each of the other categories. Similar results were seen for COO combined with the 
immune ratio.  
The optimal method to quantify net anti-tumoural immunity is unknown. 
Immune-effector:checkpoint ratios were prognostic, demonstrating the robustness of 
this simple approach to capture the relative balance of immune-effectors to 
checkpoints within the TME as a measure of net anti-tumoural immunity. The immune 
molecules quantified are all known to be enriched in DLBCL biopsies. Based on its 
superior discrimination of survival curves, the CD4*CD8:M2*PD-L1 ratio was 
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evaluated as a prognosticator. Additional immune-effector and checkpoint molecules 
to those tested have been identified,34,35 and ratios using these molecules should be 
investigated for prognostic utility. 
Assays on pre-therapy patient peripheral blood enabled detailed 
characterization of immune-effectors and checkpoints upon individual cell populations. 
This showed decreased CD137-activation and elevated PD-1 on immune-effector 
cells, and also raised numbers of the immunosuppressive moMDSC monocyte subset 
relative to healthy participants. Notably, circulating immune-effector:checkpoint cell 
ratios were associated with interim-PET/CT, as was PD-1 on CD4, CD8 and NK-cells, 
emphasizing the interplay between immune-effectors and checkpoints as predictors 
of outcome.  
Blood characterization provided interesting insights. For example, the 
correlation between CD163 (an M2-TAM marker) and HLA-DRlo on circulating 
CD14+monocytes, and the expression of lymphoid migration molecules on 
CD163himoMDSC support a link between circulating moMDSC and M2-TAMs. Also 
cell surface expression of CD163himoMDSC was enriched in PD-L1 relative to 
CD163lomoMDSC. This indicates moMDSC as one source of PD-L1 and raises the 
possibility that cell-free biomarkers of moMDSC might have prognostic value. Indeed, 
it is known that sPD-L1 predicts OS after R-CHOP,28 whereas to our knowledge this 
is the first time sCD163 has been investigated in DLBCL. However, although both 
circulating sCD163 and sPD-L1 were high pre-therapy, they displayed different 
kinetics (only sCD163 declined by post-cycle 4), indicating that as cell-free proteins 
CD163 and PD-L1 behaved independently. In keeping with this and in line with 
observations in Hodgkin Lymphoma and DLBCL, sCD163 but not sPD-L1 was 
associated with stage and lymphopenia.27,28 However, neither post-cycle 4 sCD163 
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nor sPD-L1 were differentially expressed in interim-PET/CT+ve/-ve patients, nor were 
post-cycle 4 sCD163 and sPD-L1 associated with interim-PET/CT status. These 
results indicate limited utility of these molecules as cell-free biomarkers of disease 
response in DLBCL during R-CHOP immunochemotherapy, in contrast to our previous 
data for sCD163 in Hodgkin Lymphoma.26 
Our data emphasizes the utility of capturing net anti-tumoural immunity by a 
simple ratio. The findings should be seen within the context that immune-based 
strategies are gaining ground in DLBCL.36 Blockade of the PD-1/PD-L1-axis is 
promising,22 and strategies that target CD163 may be similarly beneficial.37 In solid-
organ tumours, therapeutic PD-1 blockade is more effective in cancers enriched with 
immune-effectors that are negatively regulated by PD-1/PD-L1-axis mediated 
inhibition.38 In recent clinical trials of solid-organ and haematological cancers, it 
appears that levels of PD-1 on tumour-infiltrating lymphocytes is less predictive of 
response to PD-1 blockade than PD-L1 expression.39,40 Immune ratios measured by 
digital hybridization technologies applicable to FFPE, may permit rational selection of 
patients in whom checkpoint-blockade should be tested. 
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Figure Legends 
Figure 1. Kaplan–Meier estimates of survival of the Australian-tissue cohort of 
DLBCL patients treated with R-CHOP for high and low immune ratio 
CD4*CD8:M2*PD-L1.  
A) All patients; B) VG/G R-IPI; C) Poor R-IPI; D) GCB patients; E) non-GCB; F) Poor-
risk (Poor R-IPI-low-ratio and/or non-GCB-low-ratio) versus good-risk (remaining 
patients).  
 
Figure 2. Pre-therapy immune-effectors and checkpoints in DLBCL patients 
stratified by interim-PET/CT after 4 cycles of R-CHOP.  
A-D) Pre-therapy PD-1 on CD4, CD8 and NK-cells and CD163+moMDSC (CD14+HLA-
DRlo) grouped by post-cycle 4 interim-PET/CT results. E-G) Pre-therapy lymphocyte 
subset: CD163+moMDSC ratios grouped by post-cycle 4 interim-PET/CT results.  
 
Figure 3. Soluble CD163 is elevated in DLBCL. 
A) Plasma sCD163 is elevated in pre-therapy DLBCL patients compared to post-cycle 
4 (paired analysis) and both pre-therapy and post-cycle 4 sCD163 are elevated 
relative to healthy participants. B) ROC analysis of plasma CD163 levels in pre-
therapy DLBCL patients and healthy participants. C-F) Plasma sCD163 was inversely 
associated with absolute lymphocyte counts (using a median cut-off for 120/ml), 
advanced stage, age >60 years; higher IPI. Panels A, C-F show mean and SEM. 
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Table Legends 
Table 1. Characteristics of the ALLGNHL21, Australian-tissue and ‘Lenz’ R-
CHOP-like cohorts.  
ALLGNHL21 was a prospective study of poor-risk DLBCL, reflected in younger age 
and higher R-IPI than an unselected DLBCL population. *Age, sex and R-IPI were 
unavailable in 5, 2 and 6 patients respectively. **Eligibility criteria for NHL21 was 
based on IPI not R-IPI. R-IPI VG/G is equivalent to IPI 0-2 and Poor is equivalent to 
IPI 3-5. R-IPI was available in 199 of 233 patients in the Lenz cohort. 
 
Table 2. 4-year survival stratified by high vs low immune ratios in the Australian-
tissue cohort.  
Survival analysis, stratified by prognostic grouping, performed using Kaplan–Meier 
method and compared using the log-rank test. *There were 152 patients with R-IPI 
data.  
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